<DOC>
	<DOCNO>NCT02432846</DOCNO>
	<brief_summary>The purpose study compare tumor response , progression free survival ( PFS ) overall survival ( OS ) newly diagnose mRCC patient treat Intuvax pre-nephrectomy follow Sunitinib post-nephrectomy v Sunitinib post-nephrectomy non-vaccinated patient .</brief_summary>
	<brief_title>Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed Sunitinib Post-nephrectomy v Sunitinib Post-nephrectomy Newly Diagnosed Metastatic Renal Cell Carcinoma ( mRCC )</brief_title>
	<detailed_description>Patients , plan nephrectomy , stratify accord Heng risk criterion ( 36 high risk patient , 54 intermediate risk patient ) randomize 2:1 ratio receive Intuvax+ Sunitinib Sunitinib alone . Two dos Intuvax administer primary tumour nephrectomy . The control group schedule nephrectomy directly . All patient start Sunitinib treatment 5-8 week operation . Results phase I study , together result report literature use autologous dendritic cell ( DCs ) combination Sunitinib encourage Immunicum AB investigate possibility exploit Intuvax vaccination combine Sunitinib treatment mRCC patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Newly ( &lt; 6 month ) diagnose RCC ( histological/cytological verification optional ) least one ( 1 ) CTverified metastasis ≥10mm complete metastasectomy plan . US patient must verify clearcell tumor histology 2 . Planned resection primary tumor 3 . Primary tumor diameter ≥40 mm 4 . Candidate firstline therapy sunitinib initiate 58 week nephrectomy 5 . Female male ≥18 year age 6 . Willing able provide inform consent 7 . Adequate hematological parameter , i.e : BLeukocyte count ≥4.5 x10e9/L BPlatelet count ≥150 x10e9/L BHemoglobin ≥90 g/L 8 . Screatinine Sbilirubin ≤ 1.5 x ULN . SALAT SASAT ≤ 2.5 x ULN ( ≤5 case liver metastasis ) 9 . Female postmenopausal one ( 1 ) year female childbearing potential agree use highly efficient method contraception ( i.e . method le 1 % failure rate [ e.g . sterilization , hormone implant , hormone injection , intrauterine device , vasectomized partner combine birth control pills ] ) Female childbearing potential must negative Screening 90 day last dose INTUVAX and/or complete sunitinib treatment whichever occur later.blood pregnancy test Screening , randomize vaccination negative blood urine pregnancy test within one ( 1 ) day dose Intuvax ) must lactate . Male agree use condom Screening 90 day last dose INTUVAX and/or complete sunitinib treatment whichever occurs later , male female partner use highly efficient method contraception describe . 1 . Life expectancy le 4 month 2 . CNS metastasis symptomatic progress untretaed require current therapy ( e.g . evidence new enlarge CNS metastasis new neurological symptom attributable CNS metastasis ) 3 . Active autoimmune disease require treatment systemic immunosuppressive agent , e.g . inflammatory bowel disease , multiple sclerosis , sarcoidosis , psoriasis , autoimmune hemolytic anemia , rheumatoid arthritis , systemic lupus erythematosus ( SLE ) , vasculitis , Sjögren 's syndrome , scleroderma , autoimmune hepatitis , rheumatological disease 4 . Treatment per oral systemic corticosteroid exceed 10mg/day within seven ( 7 ) day Screening nephrectomy ( inhale , intranasal local steroid accept irrespective dose ) 5 . Known cardiomyopathy and/or clinical significant abnormal ECG finding Screening disqualify patient nephrectomy subsequent sunitinib treatment 6 . Karnofsky performance status &lt; 70 % 7 . National Cancer Institute ( NCI ) Common Terminology criterion Adverse Events ( CTCAE ) Grade 3 hemorrhage within 28 day Screening 8 . Preexisting thyroid abnormality thyroid function maintain normal range medication 9 . Clinically significant gastrointestinal abnormality 10 . Uncontrolled hypertension , uncontrolled diabetes mellitus 11 . Pulmonary embolism within 12 month screen 12 . Prior history invasive cancer within 5 year screen , except adequately treat situ carcinoma nonmelanoma skin cancer 13 . Ongoing infection require parenteral treatment antibiotic 14 . Active latent virus disease ( HIV , hepatitis B hepatitis C ) 15 . ECOG performance status &gt; 2 optimization analgesic 16 . Abnormal clinical significant coagulation parameter discretion Investigator , i.e . : Prothrombin Time International Normalized Ratio ( PTINR ) Activated Partial Thromboplastin Time ( APTT ) patient beeing treated anticoagulant exclude teh coagulation parameter outside therapeutic interval describe SmPC/USPI administer treatment 17 . Known major adverse reaction/event connection previously make vaccination ( e.g . asthma , anaphylaxis serious reaction ) 18 . Known hypersensitivity allergy sunitinib chemically relate product likely exacerbate component study product 19 . Prior systemic antitumour therapy within 28 day Screening Visit . However , local radiation therapy area except abdominal/retroperitoneal area include kidney tumour allow 20 . Exposure investigational product within 28 day prior Screening Visit 21. patient anticoagulant temporarily stop start , support low molecular weight heparin ( anticoagulation therapy discretion investigator per local standard care ) vaccination nephrectomy , option 22 . History alcohol substance abuse 23 . Any reason , opinion Investigator , contraindicate patient participates study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>